Search results
Alzheon secures $100m to advance Alzheimer’s disease treatment
Pharmaceutical Technology via Yahoo Finance· 5 hours agoClinical-stage biopharmaceutical company Alzheon has secured $100m in a Series E funding round to...
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab
Zacks via Yahoo Finance· 24 hours agoIf Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by...
A look at Alzheimer’s Disease and how to care for your loved one
KNOE Monroe LA· 12 hours agoAccording to the Alzheimer’s Association, over 95,000 people in Louisiana are living with Alzheimer’s disease. < ...
Eli Lilly's Potential Alzheimer’s Drug Clears a Big Hurdle
Time via Yahoo News· 2 days agoCredit - Fotografixx—Getty Images After many years of slow progress, drug companies searching for...
Thousands face missing out on new Alzheimer’s treatments unless testing overhauled
The Telegraph via Yahoo News· 1 day agoThe new treatments have been shown to slow the disease's progression by as much as 60 per cent in...
Alzheimer’s Foundation of America encouraged by new drug closer to FDA approval
WBRC Fox 6 Birmingham· 1 day agoFederal health advisers are recommending a new Alzheimer’s drug from Eli Lilly that slows the...
Annovis Bio plans large study to test experimental drug in earlyAlzheimer's patients - The Business...
The Business Journals· 2 hours agoAnnovis Bio, based on analysis of the mixed results from its most recent study, plans to focus the...
‘Reversing’ Alzheimer’s: Here are exercises to make the brain more resilient
Fox News· 1 day agoCan Alzheimer’s disease be reversed? Dr. Heather Sandison, a renowned expert in Alzheimer’s disease...
Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod
Zacks via Yahoo Finance· 2 days agoEarlier data presented by Lilly from the study showed that treatment with donanemab significantly...
New Alzheimer’s treatment could bring hope to local families impacted by the disease
WPXI via Yahoo News· 15 hours agoEli Lilly developed a drug called Donanemab. “This is potentially the third FDA-approved medication for the actual treatment of the underlying biology of Alzheimer’